FrancophonIA/ELRC3.0 huggingface dataset:
English: Uncommon (may affect up to 1 in 100 people) - Systemic body inflammation, caused by infection of the gall bladder and bile ducts (biliary sepsis) - Allergic reaction to ONIVYDE pegylated liposomal (the active substance or the excipients) - Diminished availability of oxygen to the body tissues - Inflammation of the oesophagus (food pipe) - Formation or presence of a blood clot within a blood vessel - vein or artery (thrombosis) - Inflammation of the lining of the rectum (the end of the large intestine) - Type of rash, characterised by appearance of a flat, red area on the skin covered with bumps
Danish: Ikke almindelig (forekommer hos op til 1 ud af 100 patienter) - Betændelse i hele kroppen forårsaget af infektion i galdeblæren og galdegangene (biliær sepsis) - Allergisk reaktion over for ONIVYDE pegyleret liposomal (det aktive stof eller hjælpestofferne) - Nedsat iltforsyning til kroppens væv - Inflammation i spiserøret - Dannelse eller tilstedeværelse af en blodprop i en blodåre - vene eller arterie (trombose) - Inflammation i endetarmens slimhinde - En særlig type udslæt, som er kendetegnet ved et fladt, rødt hudområde, der er dækket af buler
English: Liposome forming lipids
Danish: Lipider i liposom
English: • ONIVYDE pegylated liposomal is a cytotoxic medicinal product and caution should be exercised in handling it.
Danish: • ONIVYDE pegyleret liposomal er et cytotoksisk lægemiddel, og der skal udvises forsigtighed ved håndteringen.
English: Interaction affecting the use of ONIVYDE pegylated liposomal
Danish: Interaktion, som påvirker brugen af ONIVYDE pegyleret liposomal
English: Irinotecan released from liposome encapsulation follows a similar metabolic pathway reported with non-liposomal irinotecan.
Danish: Irinotecan, der frigives fra liposomindkapslingen, følger samme metaboliseringsvej, som er rapporteret for nonliposomal irinotecan.
English: headache, tightness in the chest or throat - Abnormal fluid retention in the body causing swelling in the affected tissues (oedema)
Danish: hovedpine, trykken for brystet eller en snørende fornemmelse omkring halsen - Unormal væskeophobning i kroppen, som giver hævelse i det påvirkede væv (ødem)
English: ONIVYDE pegylated liposomal is a liposomal formulation of irinotecan with different pharmacokinetic properties compared to non-liposomal irinotecan.
Danish: ONIVYDE pegyleret liposomal er en liposomal formulering af irinotecan, som har andre farmakokinetiske egenskaber end nonliposomal irinotecan.
English: Non haematological toxicities
Danish: Ikke-hæmatologiske toksiciteter
English: Myelosuppression (neutropenia/leukopenia, thrombocytopenia and, anaemia) was more common in the ONIVYDE pegylated liposomal +5-FU/LV arm compared to the 5-FU/LV control arm.
Danish: Myelosuppression (neutropeni/leukopeni, trombocytopeni og anæmi) var hyppigere i ONIVYDE pegyleret liposomal + 5-FU/LV-gruppen end i 5-FU/LV-kontrolgruppen.
English: ONIVYDE pegylated liposomal should be discontinued in patients with a confirmed diagnosis of ILD.
Danish: ONIVYDE pegyleret liposomal bør seponeres hos patienter med bekræftet ILS-diagnose.
English: In the clinical study Grade 3 or Grade 4 diarrhoea occurred in 15 out of 117 patients (12.8%) receiving ONIVYDE pegylated liposomal +5-FU/LV.
Danish: I det kliniske studie forekom diarré af grad 3 eller 4 hos 15 ud af 117 patienter (12,8 %), som fik ONIVYDE pegyleret liposomal + 5-FU/LV.
English: Interstitial Lung Disease (ILD)-like events leading to fatalities have occurred in patients receiving non-liposomal irinotecan.
Danish: Der er set ILS- (interstitiel lungesygdom) lignende bivirkninger, som kan være dødelige, hos patienter, som har fået nonliposomal irinotecan.
English: Pregnant staff should not handle ONIVYDE pegylated liposomal considering the cytotoxic nature of the medicinal product.
Danish: ONIVYDE pegyleret liposomal må ikke håndteres af gravide på grund af lægemidlets cytotoksiske karakter.
English: The most common serious adverse reactions (≥ 2%) of ONIVYDE pegylated liposomal therapy were diarrhoea, vomiting, febrile neutropenia, nausea, pyrexia, sepsis, dehydration, septic shock, pneumonia, acute renal failure, and thrombocytopenia.
Danish: De hyppigste alvorlige bivirkninger (≥ 2 %) ved ONIVYDE pegyleret liposomal-behandlingen var diarré, opkastning, febril neutropeni, kvalme, pyreksi, sepsis, dehydrering, septisk shock, pneumoni, akut nyresvigt og trombocytopeni.
English: ONIVYDE pegylated liposomal should not be administered with strong UGT1A inhibitors (e.g. atazanavir, gemfibrozil, indinavir) unless there are no therapeutic alternatives.
Danish: ONIVYDE pegyleret liposomal bør ikke indgives samtidig med potente UGT1A-hæmmere (f.eks. atazanavir, gemfibrozil, indinavir), medmindre der ikke findes andre behandlingsmuligheder.
English: Compared to Caucasian patients, Asian patients have an increased risk of severe and febrile neutropenia following treatment with ONIVYDE pegylated liposomal +5-FU/LV (see sections 4.8 and 5.2).
Danish: Asiatiske patienter har i sammenligning med kaukasiere øget risiko for svær og febril neutropeni efter behandling med ONIVYDE pegyleret liposomal + 5-FU/LV (se pkt.
English: The most frequently reported adverse reactions leading to discontinuation were infection and diarrhoea for ONIVYDE pegylated liposomal +5-FU/LV arm, and vomiting and diarrhoea for the monotherapy arm.
Danish: De hyppigst rapporterede bivirkninger, som medførte seponering, var infektion og diarré i ONIVYDE pegyleret liposomal + 5-FU/LV-gruppen og opkastning og diarré i monoterapigruppen.
English: Very common: Neutropenia, Leukopenia, Anaemia, Thrombocytopenia
Danish: Meget almindelig: Neutropeni, leukopeni, anæmi, trombocytopeni
English: Do not throw away this medicine via wastewater or household waste.
Danish: Af hensyn til miljøet må du ikke smide medicinrester i afløbet, toilettet eller skraldespanden.
English: Diarrhoea is a very common adverse reaction leading to colitis, ileus, gastroenteritis, fatigue, dehydration, weight loss, renal toxicities, hyponatraemia, and hypokalaemia.
Danish: Diarré er en meget almindelig bivirkning, som kan medføre kolitis, ileus, gastroenteritis, træthed, dehydrering, vægttab, renal toksicitet, hyponatriæmi og hypokaliæmi.
English: OTHER SPECIAL WARNING(S), IF NECESSARY Onivyde pegylated liposomal (irinotecan) is not equivalent to non-liposomal formulations.
Danish: EVENTUELLE ANDRE SÆRLIGE ADVARSLER ONIVYDE pegyleret liposomal (irinotecan) svarer ikke til nonliposomale formuleringer.
English: ONIVYDE pegylated liposomal should not be administered with strong CYP3A4-enzyme inhibitors (e.g. grapefruit juice, clarithromycin, indinavir, itraconazole, lopinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telaprevir, voriconazole).
Danish: ONIVYDE pegyleret liposomal bør ikke indgives samtidig med potente CYP3A4-enzymhæmmere (f.eks. grapefrugtjuice, clarithromycin, indinavir, itraconazol, lopinavir, nefazodon, nelfinavir, ritonavir, saquinavir, telaprevir, voriconazol).
English: Patients homozygous for the UGT1A1*28 allele were given a lower initial dose of ONIVYDE pegylated liposomal (see section 4.2).
Danish: Patienter, som var homozygote for UGT1A1*28-allellen, fik en lavere initialdosis af ONIVYDE pegyleret liposomal (se pkt.
English: Intravenous use after dilution.
Danish: Intravenøs administration efter fortynding.
English: One ml of concentrate contains 0.144 mmol (3.31 mg) sodium.
Danish: 1 ml af dette lægemiddel indeholder 0,144 mmol (3,31 mg) natrium.
English: Grade 3 or Grade 4 (< 1,000 cells/mm3) or
Danish: Grad 3 eller 4 (< 1.000
English: Nausea/vomiting
Danish: Kvalme/opkastning
English: ONIVYDE pegylated liposomal contains sodium
Danish: ONIVYDE pegyleret liposomal indeholder natrium
English: Therefore, co-administration of ONIVYDE pegylated liposomal with other inhibitors of CYP3A4 (e.g. grapefruit juice, clarithromycin, indinavir, itraconazole, lopinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telaprevir, voriconazole) may increase systemic exposure of ONIVYDE pegylated liposomal.
Danish: Administration af ONIVYDE pegyleret liposomal sammen med andre CYP3A4-hæmmere (f.eks. grapefrugtjuice, clarithromycin, indinavir, itraconazol, lopinavir, nefazodon, nelfinavir, ritonavir, saquinavir, telaprevir, voriconazol) kan derfor øge den systemiske eksponering for ONIVYDE pegyleret liposomal.
English: Non-liposomal irinotecan mean (SD) 125 mg/m
Danish: Nonliposomal irinotecan 125 mg/m (n = 99)
English: Name and address of the manufacturer(s) responsible for batch release Les Laboratoires Servier Industrie
Danish: Navn og adresse på den fremstiller, der er ansvarlig for batchfrigivelse
English: Your doctor may also prescribe other medicines to help control your side effects.
Danish: Lægen vil eventuelt udskrive medicin til at afhjælpe bivirkningerne.
English: Renal impairment and acute renal failure have been identified, usually in patients who become volume depleted from nausea/vomiting and/or diarrhoea.
Danish: Nedsat nyrefunktion og akut nyresvigt er set, sædvanligvis hos patienter med hypovolæmi som følge af kvalme/opkastning og/eller diarré.
English: A reduced starting dose of ONIVYDE pegylated liposomal (irinotecan) of 50 mg/m should be considered for patients known to be homozygous for the UGT1A1*28 allele (see sections 4.8 and 5.1).
Danish: En reduceret startdosis af ONIVYDE pegyleret liposomal (irinotecan) på 50 mg/m bør overvejes til patienter, som er kendt homozygote for UGT1A1*28-allellen (se pkt.
English: AUC= area under the plasma concentration curve (extrapolated to infinity for ONIVYDE pegylated liposomal and AUC24h for non-liposomal irinotecan) Cmax= maximum plasma concentration t1/2 effective= effective half-lives
Danish: AUC = arealet under plasmakoncentrationskurven (ekstrapoleret til uendelig for ONIVYDE pegyleret liposomal og AUC24timer for nonliposomal irinotecan).
English: Patients with a history of a Whipple procedure have a higher risk of serious infections following ONIVYDE pegylated liposomal in combination with 5-FU and leucovorin (see section 4.8).
Danish: Patienter, som har fået foretaget Whipples operation, har større risiko for alvorlige infektioner efter ONIVYDE pegyleret liposomal i kombination med 5-FU og leucovorin (se pkt.
English: A new cycle of therapy should not begin until nausea/vomiting resolves to ≤ Grade 1 or baseline
Danish: En ny behandlingscyklus bør ikke påbegyndes, før kvalme/opkastning er reduceret til ≤ grad 1 eller baseline-niveau.
English: It is especially important that you tell your doctor if you are also taking the following medicines, since they increase the availability of irinotecan in your body: - ketoconazole, itraconazole or voriconazole (medicines used to treat fungal infections) - clarithromycin (an antibiotic medicine used to treat bacterial infections) - indinavir, lopinavir, nelfinavir, ritonavir, saquinavir, atazanavir (medicines against HIV
Danish: Det er særligt vigtigt, at du fortæller lægen, hvis du også bruger nogle af følgende lægemidler, da de kan øge virkningen af irinotecan: - ketoconazol, itraconazol eller voriconazol (mod svampeinfektioner) - clarithromycin (antibiotikum mod bakterieinfektioner) - indinavir, lopinavir, nelfinavir, ritonavir, saquinavir, atazanavir (mod HIV-infektion) - telaprevir (mod leversygdommen hepatitis C) - nefazodon (mod depression og nedtrykthed) - gemfibrozil (mod forhøjet fedt i blodet)
English: It is also especially important that you tell your doctor if you are also taking the following medicines, since they reduce the availability of irinotecan in your body: - phenytoin, phenobarbital or carbamazepine (medicines used to treat convulsions and falls) - rifampicin and rifabutin (medicines used to treat tuberculosis) - St. John´s wort (a plant based medicine used to treat depression and low mood) - as ONIVYDE pegylated liposomal should not be given to you together with these medicines.
Danish: Desuden er det særligt vigtigt, at du fortæller lægen, hvis du også bruger nogle af følgende lægemidler, da de kan nedsætte virkningen af irinotecan: - phenytoin, phenobarbital eller carbamazepin (mod kramper og fald) - rifampicin og rifabutin (mod tuberkulose) - perikon (naturlægemiddel mod depression og nedtrykthed)
English: Common: Hypoalbuminaemia
Danish: Almindelig: Hypoalbuminæmi
English: Once the concentrate has been diluted for infusion with 5% glucose solution for injection or sodium chloride 9 mg/ml (0.9%) solution for injection, the solution should be used as soon as possible, but may be stored at ambient temperature (15°C to 25°C) for up to 6 hours.
Danish: Når koncentratet er fortyndet til en infusionsvsæke med 5 % glucoseinjektionsvæske eller 9 mg/ml (0,9 %) natriumchloridinjektionsvæske, skal infusionsvæske anvendes så hurtigt som muligt, men kan opbevares ved stuetemperatur (15-25 °C) i op til 6 timer og i køleskab (2-8 °C) i højst 24 timer før brug.
English: No findings indicative of CNS related toxicity were observed in the repeated dose toxicity studies in rats.
Danish: I toksicitetsstudier med gentagne doser på rotter blev der ikke observeret nogen fund, som indikerede CNS-relateret toksicitet.
English: In a population pharmacokinetic analysis, patients with baseline total bilirubin concentrations of 1-2 mg/dl (n=19) had average steady state concentrations for total SN-38 that were increased by 37% (0.98 [95%CI: 0.94-1.02] and 1.29 [95%CI: 1.11-1.5] ng/ml, respectively) compared to patients with baseline bilirubin concentrations of < 1 mg/dl (n=329); however, there was no effect of elevated ALT/AST concentrations on total SN-38 concentrations.
Danish: I en populationsfarmakokinetisk analyse havde patienter med total-bilirubin på 1-2 mg/dl (n = 19) ved baseline en gennemsnitlig steady state-koncentration af total-SN-38, som var 37 % højere end patienter med baseline-bilirubin < 1 mg/dl (n = 329) (henholdsvis 0,98 (95 % CI: 0,94-1,02) og 1,29 (95 % CI: 1,11-1,5) ng/ml).
English: In the clinical trial demonstrating effectiveness of ONIVYDE pegylated liposomal, higher plasma exposures of total irinotecan and SN-38 for patients in the ONIVYDE pegylated liposomal +5-FU/LV treatment arm were associated with longer OS and PFS as well as with higher ORR (objective response rate).
Danish: I det kliniske forsøg, der undersøgte effekten af ONIVYDE pegyleret liposomal, var højere plasmaeksponering for total-irinotecan og total-SN-38 hos patienterne i ONIVYDE pegyleret liposomal + 5-FU/LV-gruppen forbundet med længere OS og PFS samt højere ORR.
English: - if you experience sudden shortness of breath, flushing, nausea, headache, skin rash or hives (itchy rash with swollen red bumps on the skin that appear suddenly), itching, swelling around the eyes, tightness in the chest or throat during the infusion or shortly after it (as the infusion may need to be stopped and you may need to be treated or observed for the side effects) - if you get fever, chills and signs of an infection (as this might require immediate treatment) - if you have severe persistent diarrhoea (liquid and frequent stools)-see section 2
Danish: - Hvis du får pludseligt åndedrætsbesvær, ansigtsrødme, kvalme, hovedpine, hududslæt eller nældefeber (pludseligt får kløende udslæt med hævede røde buler på huden), kløe, hævelse omkring øjnene, trykken for brystet eller en snørende fornemmelse omkring halsen under eller kort efter infusionen (da det kan være nødvendigt at standse infusionen, og du måske skal behandles eller observeres for disse bivirkninger).
English: ONIVYDE pegylated liposomal (irinotecan) is not equivalent to non-liposomal irinotecan formulations and should not be interchanged.
Danish: ONIVYDE pegyleret liposomal (liposomal irinotecan) er ikke ækvivalent med nonliposomale formuleringer af irinotecan, og de må ikke udskiftes indbyrdes.
English: Adverse reaction frequency** Infections and infestations Common: Septic shock, Sepsis, Pneumonia, Febrile neutropenia, Gastroenteritis, Oral candidiasis Uncommon: Biliary sepsis
Danish: Almindelig: Septisk shock, sepsis, pneumoni, febril neutropeni, gastroenteritis, oral candidiasis
English: ONIVYDE pegylated liposomal /5-FU adjustment (for patients homozygous for UGT1A1*28 without previous increase to 70 mg/m
Danish: Justering af ONIVYDE pegyleret liposomal/5-FU (for patienter, der er homozygote for UGT1A1*28 uden forudgående dosisøgning til 70 mg/m
English: Acute infusion reactions were reported in 8 of 117 patients (6.8%) in the ONIVYDE pegylated liposomal +5-FU/LV arm, 3 of 147 patients (2.0%) in the ONIVYDE pegylated liposomal monotherapy arm, and 8 of 134 patients (6.0%) in the 5-FU/LV arm.
Danish: Akutte infusionsreaktioner blev rapporteret hos 8 ud af 117 patienter (6,8 %) i ONIVYDE pegyleret liposomal + 5-FU/LV-gruppen, hos 3 ud af 147 patienter (2,0 %) i ONIVYDE pegyleret liposomal-monoterapigruppen og hos 8 ud af 134 patienter (6,0 %) i 5-FU/LV-gruppen.
English: Because of the potential for serious adverse reactions of ONIVYDE pegylated liposomal in breast-feeding infants, ONIVYDE pegylated liposomal is contraindicated during breast-feeding (see section 4.3).
Danish: På grund af de potentielt alvorlige bivirkninger ved ONIVYDE pegyleret liposomal hos det ammede barn er ONIVYDE pegyleret liposomal kontraindiceret til ammende kvinder (se pkt.
English: ONIVYDE pegylated liposomal must not be administered as a bolus injection or an undiluted solution.
Danish: ONIVYDE pegyleret liposomal må ikke indgives som bolusinjektion eller ufortyndet.
English: Strong CYP3A4 inducers
Danish: Potente CYP3A4-induktorer
English: ONIVYDE pegylated liposomal is a cytotoxic medicinal product, and caution should be exercised in handling it.
Danish: ONIVYDE pegyleret liposomal er et cytotoksisk lægemiddel, og der skal udvises forsigtighed ved håndteringen.
English: No cases of ILD-like events have been reported with ONIVYDE pegylated liposomal therapy in clinical studies.
Danish: Der er ikke rapporteret ILS-lignende bivirkninger ved ONIVYDE pegyleret liposomal-behandling i kliniske studier.
English: ONIVYDE pegylated liposomal is not equivalent to other non-liposomal irinotecan formulations and should not be interchanged.
Danish: ONIVYDE pegyleret liposomal er ikke ækvivalent med nonliposomale formuleringer af irinotecan, og de må ikke udskiftes indbyrdes.
English: ONIVYDE pegylated liposomal should not be administered with strong CYP3A4-enzyme inducers such as anticonvulsants (phenytoin, phenobarbital or carbamazepine), rifampin, rifabutin and St. John's wort unless there are no therapeutic alternatives.
Danish: ONIVYDE pegyleret liposomal bør ikke indgives samtidig med potente CYP3A4-enzyminduktorer, f.eks. antikonvulsiva (phenytoin, phenobarbital eller carbamazepin), rifampin, rifabutin og perikon, medmindre der ikke findes andre behandlingsmuligheder.
English: Tell your doctor if you are breast-feeding.
Danish: Fortæl det til lægen, hvis du ammer.
English: Caution should be exercised in patients receiving concurrent administration of ONIVYDE pegylated liposomal with irradiation.
Danish: Der skal udvises forsigtighed hos patienter, som får ONIVYDE pegyleret liposomal samtidig med strålebehandling.
English: Reduce 5-FU dose by an additional 25% (1,350 mg/m
Danish: Reducer ONIVYDE pegyleret liposomal-dosis til 43 mg/m Reducer 5-FU-dosis med yderligere 25 % (1.350 mg/m
English: Underweight patients (body mass index < 18.5 kg/m2)
Danish: Undervægtige patienter (BMI < 18,5 kg/m2)
English: (anaemia) - Low level of blood platelets (thrombocytopenia) - Diarrhoea (loose or watery and frequent stools) - Nausea and vomiting - Pain in the stomach or in the gut area - Sore mouth - Loss of weight - Loss of appetite - Loss of body fluid (dehydration) - Low level of salts (electrolytes) in the body (e.g. of potassium, magnesium) - Unusual hair loss - Tiredness - Dizziness - Swelling and fluid retention in the soft tissues (peripheral oedema)
Danish: (blodmangel) - Lav antal blodplader (trombocytopeni) - Diarré (hyppig løs eller vandig afføring) - Kvalme og opkastning - Smerter i maven eller mave-tarm-regionen - Ømhed i munden - Vægttab - Appetitløshed - Væskemangel (dehydrering)
English: Dilute with 5% glucose solution for injection or sodium chloride 9 mg/ml (0.9%) solution for injection to prepare a solution of the appropriate dose of ONIVYDE pegylated liposomal diluted to a final volume of 500 ml.
Danish: Fortynd med 5 % glucoseinjektionsvæske eller 9 mg/ml (0,9 %) natriumchloridinjektionsvæske for at fremstille en infusionsvæske med den korrekte dosis af ONIVYDE pegyleret liposomal fortyndet til et endeligt volumen på 500 ml.
English: Patients randomised to 5-FU/LV received leucovorin 200 mg/m intravenously over 30 minutes, followed by 5-FU 2,000 mg/m intravenously over 24 hours, administered on Days 1, 8, 15 and 22 of a 6 week cycle.
Danish: 5-FU intravenøst over 24 timer indgivet på dag 1, 8, 15 og 22 i en 6-ugerscyklus.
English: Following recovery to Grade 1 diarrhoea, resume ONIVYDE pegylated liposomal at a reduced dose (see section 4.2).
Danish: Efter reduktion af diarréen til grad 1, genoptages behandlingen med ONIVYDE pegyleret liposomal med reduceret dosis (se pkt.
English: History of severe hypersensitivity to irinotecan or to any of the excipients listed in section 6.1.
Danish: Tidligere svær overfølsomhed over for irinotecan eller over for et eller flere af hjælpestofferne anført i pkt.
English: Information about drug interactions with ONIVYDE pegylated liposomal is referenced from the published scientific literature for nonliposomal irinotecan.
Danish: 4.5 Interaktion med andre lægemidler og andre former for interaktion Information om lægemiddelinteraktioner med ONIVYDE pegyleret liposomal stammer fra publiceret videnskabelig litteratur vedrørende nonliposomal irinotecan.
English: Dilute with 5% glucose solution for injection or sodium chloride 9 mg/ml (0.9%) solution for injection to prepare a dispersion of the appropriate dose of ONIVYDE pegylated liposomal diluted to a final volume of 500 ml.
Danish: Fortynd med 5 % glucoseinjektionsvæske eller 9 mg/ml (0,9 %) natriumchloridinjektionsvæske for at fremstille en opløsning med den korrekte dosis af ONIVYDE pegyleret liposomal fortyndet til et endeligt volumen på 500 ml.
English: Very common: Weight decrease
Danish: Meget almindelig: Vægttab
English: Early onset diarrhoea may be accompanied by cholinergic symptoms such as rhinitis, increased salivation, flushing, diaphoresis, bradycardia, miosis and hyperperistalsis.
Danish: Tidligt indsættende diarré kan ledsages af kolinerge symptomer som rinitis, øget spytsekretion, ansigtsrødme, diaforese, bradykardi, miosis og øget peristaltik.
English: In the clinical study evaluating ONIVYDE pegylated liposomal +5-FU/LV, 5 of 8 underweight patients experienced a Grade 3 or 4 adverse reactions, mostly myelosuppression, while 7 of the 8 patients required dose modification such as dose delay, dose reduction or dose discontinuation.
Danish: I det kliniske studie, der evaluerede ONIVYDE pegyleret liposomal + 5-FU/LV, oplevede 5 ud af 8 undervægtige patienter en bivirkning af grad 3 eller 4, især myelosuppression, mens dosisændring, f.eks. udskydelse af dosis, dosisreduktion eller seponering var nødvendig hos 7 ud af 8 patienter.
English: LV 400 mg/m intravenously over 30 minutes, followed by 5-FU 2,400 mg/m intravenously over 46 hours, administered every 2 weeks.
Danish: LV intravenøst over 30 minutter efterfulgt af 2.400 mg/m
English: Acute renal failure was reported in 6 of 117 patients (5.1%) in the ONIVYDE pegylated liposomal +5-FU/LV arm, 10 of 147 (6.8%) in the ONIVYDE pegylated liposomal monotherapy arm and 6 of 134 patients (4.5%) in the 5-FU/LV arm.
Danish: Akut nyresvigt blev rapporteret hos 6 ud af 117 patienter (5,1 %) i ONIVYDE pegyleret liposomal + 5-FU/LV-gruppen, hos 10 ud af 147 patienter (6,8 %) i ONIVYDE pegyleret liposomal-monoterapigruppen og hos 6 ud af 134 patienter (4,5 %) i 5-FU/LV-gruppen.
English: Early onset diarrhoea may also be accompanied by cholinergic symptoms that can include rhinitis, increased salivation, flushing, diaphoresis, bradycardia, miosis and hyperperistalsis that can induce abdominal cramping.
Danish: Tidligt indsættende diarré kan ledsages af kolinerge symptomer som f.eks. rinitis, øget spytsekretion, ansigtsrødme, diaforese, bradykardi, miosis og øget peristaltik, som kan forårsage abdominalkramper.